Meeting
2020 ASCO Virtual Scientific Program
Discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia in chronic phase (CML-CP) in US clinical practice after guideline updates.
Authors
Ehab L. Atallah
Hematologic Malignancies, Medical College of Wisconsin, Milwaukee, WI
Ehab L. Atallah , Islam Sadek , Rodrigo O. Maegawa , Xiting Cao , Dominick Latremouille-Viau , Irina Pivneva , Carmine Rossi , Annie Guerin , Vamsi Kota
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Chronic Leukemia—CML
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7548)
DOI
10.1200/JCO.2020.38.15_suppl.7548
Abstract #
7548
Poster Bd #
321
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Tyrosine kinase inhibitor (TKI) therapy discontinuation in patients with CML in chronic phase: A US clinical practice perspective.
First Author: Ellen K. Ritchie
Poster
2013 ASCO Annual Meeting
Treatment response monitoring in chronic phase CML (CP-CML) patients receiving tyrosine kinase inhibitor (TKI) therapy in US Oncology network.
First Author: Kathryn S. Kolibaba
Poster
2018 ASCO Annual Meeting
Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
First Author: Wendy Stock
Poster
2013 ASCO Annual Meeting
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia (CML).
First Author: Lei Chen